Hansoh Pharmaceutical Group Co (HKSE:03692) Capex-to-Operating-Income : 0.10 (As of Dec. 2023)

View and export this data going back to 2019. Start your Free Trial

What is Hansoh Pharmaceutical Group Co Capex-to-Operating-Income?

Capex-to-Operating-Income measures a company's investments in physical assets such as property, industrial buildings or equipment to its operating income.

Hansoh Pharmaceutical Group Co's Capital Expenditure for the six months ended in Dec. 2023 was HK$-183.60 Mil. Its Operating Income for the six months ended in Dec. 2023 was HK$1,919.13 Mil.

Hence, Hansoh Pharmaceutical Group Co's Capex-to-Operating-Income for the six months ended in Dec. 2023 was 0.10.

Hansoh Pharmaceutical Group Co Capex-to-Operating-Income Historical Data

The historical data trend for Hansoh Pharmaceutical Group Co's Capex-to-Operating-Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hansoh Pharmaceutical Group Co Capex-to-Operating-Income Chart

Hansoh Pharmaceutical Group Co Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Capex-to-Operating-Income

Get a 7-Day Free Trial

0.21

0.51

0.16

0.11

0.13

Hansoh Pharmaceutical Group Co Semi-Annual Data
	Dec16	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Capex-to-Operating-Income	Get a 7-Day Free Trial									0.14	0.15	0.06	0.18	0.10

Competitive Comparison of Hansoh Pharmaceutical Group Co's Capex-to-Operating-Income

For the Drug Manufacturers - Specialty & Generic subindustry, Hansoh Pharmaceutical Group Co's Capex-to-Operating-Income, along with its competitors' market caps and Capex-to-Operating-Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Hansoh Pharmaceutical Group Co's Capex-to-Operating-Income Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Hansoh Pharmaceutical Group Co's Capex-to-Operating-Income distribution charts can be found below:

* The bar in red indicates where Hansoh Pharmaceutical Group Co's Capex-to-Operating-Income falls into.

Hansoh Pharmaceutical Group Co Capex-to-Operating-Income Calculation

Hansoh Pharmaceutical Group Co's Capex-to-Operating-Income for the fiscal year that ended in Dec. 2023 is calculated as

Capex-to-Operating-Income	=	- Capital Expenditure	/	Operating Income
	=	- (-396.521)	/	3105.589
	=	0.13

Hansoh Pharmaceutical Group Co's Capex-to-Operating-Income for the quarter that ended in Dec. 2023 is calculated as

Capex-to-Operating-Income	=	- Capital Expenditure	/	Operating Income
	=	- (-183.598)	/	1919.125
	=	0.10

Hansoh Pharmaceutical Group Co (HKSE:03692) Capex-to-Operating-Income Explanation

Capex-to-Operating-Income assesses how much emphasis a company is placing upon investing in capital-intensive projects. The ratio is generally a good gauge to quantify how much focus on growth a company has. Typically, smaller companies that are still growing and expanding will have a higher Capex to Operating Income Ratio, since such businesses are likely investing more in physical assets. Lower ratios could indicate that a company has reached maturity and it is no longer pursuing aggressive growth.

Hansoh Pharmaceutical Group Co Capex-to-Operating-Income Related Terms

Thank you for viewing the detailed overview of Hansoh Pharmaceutical Group Co's Capex-to-Operating-Income provided by GuruFocus.com. Please click on the following links to see related term pages.

Hansoh Pharmaceutical Group Co (HKSE:03692) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Hansoh Pharmaceutical Group Co Ltd (HKSE:03692) » Definitions » Capex-to-Operating-Income

Traded in Other Exchanges

3KY:Germany

Address

287 Xiangke Road, Pudong New District, Shanghai, CHN, 201210

Website

https://www.hspharm.com

Hansoh Pharmaceutical Group Co Ltd is a research and development-driven pharmaceutical company in China. The company holds a broad, diversified drug portfolio in CNS diseases, oncology, anti-infectives, and diabetes. Further, it also focuses on metabolic diseases and anti-tumor. The majority of revenue is generated from the sale of pharmaceutical products in Mainland China.

Executives

Cen Junda	2307 Founder of a discretionary trust who can infl
Cantrust (far East) Limited	2301 Trustee
Jqc Holding Limited	2201 Interest of corporation controlled by you
Jqc International Limited	2201 Interest of corporation controlled by you
Sun Yuan	2101 Beneficial owner
Harmonia Holding Investing (ptc) Limited	2201 Interest of corporation controlled by you
Stellar Infinity Company Ltd.	2101 Beneficial owner
Sunrise Investment Advisors Limited	2201 Interest of corporation controlled by you
Zhong Huijuan	2307 Founder of a discretionary trust who can infl
Apex Medical Company Ltd.	2101 Beneficial owner

Hansoh Pharmaceutical Group Co (HKSE:03692) Headlines

No Headlines